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Clinical outcomesTranscatheter aortic valve implantation (TAVI) is evolving
rapidly with an exponential growth in the number of procedures in
European countries [1,2], and is now reaching relative maturity. As
worldwide experience with this modality increases, more and
more patients are being offered this alternative to open surgery
for the treatment of severe, symptomatic aortic stenosis (AS). In
Japan, TAVI started to be used from 2013 after a clinical trial which
had been successfully ﬁnished [3,4]. It has been estimated that
1400 procedures were performed in 2014, a number that will
assuredly increase.
A successful TAVI procedure needs a merging of different skills
including catheter-based guide-wire skills and ﬂuoroscopic imag-
ing, as well as a vast knowledge of open vascular approaches,
cardiac structures, and aortic root anatomy. Therefore, interven-
tional cardiologists and cardiovascular surgeons have been
confronted with the need to gain experience in these novel
approaches to aortic valve disease while maintaining high-quality
results. Although TAVI is currently becoming a standard procedure
worldwide, starting a TAVI program in a new center requires a
learning curve [5,6]. In an effort to reduce the impact of this
learning process, numerous educational methods focused on TAVI
skills and procedures are offered by industry to medical centers
desiring a TAVI program. In Japan, a good proctoring system has
been developed, the on-site proctorship and the screening
proctorship. The on-site proctor scrubs with the beginning
operator for the procedure with the aim of guiding and assisting
the trainee. At the same time, the proctor actively transfers skills to
the trainee by providing real-time feedback of trainee performance.
The screening proctors have a responsibility for the indication of
the individual case. The screening proctors consist of interventional
cardiologists, cardiac surgeons, and general cardiologists. Their
decisions keep a quality of indication which leads to safe TAVI.DOI of original article: http://dx.doi.org/10.1016/j.jccase.2015.05.006
http://dx.doi.org/10.1016/j.jccase.2015.07.002
1878-5409/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsThere are several points that concern us for which TAVI will be
accepted as a viable therapy for severe AS in Japan. Japanese
patients have a smaller body size and, consequently, a smaller
aortic annulus size and vascular access than their European
counterparts. A previous report showed that patients with small
body size had smaller annulus and valve size [7]. A comparison of
clinical outcomes between European and Japanese cohorts
undergoing TAVI demonstrated that Japanese patients had a
smaller aortic annulus as shown on echocardiography and the
most commonly used implant was the Edwards 23-mm valve in
the Japanese group and the Edwards 26-mm valve in the European
group, suggesting that smaller valves are needed for Japanese
patients [8]. The risks related to these anatomic differences have
raised concerns about the safety of TAVI in Japanese patients.
Although the anatomical difﬁculty of Japanese patients
undergoing TAVI exists, the preliminary data show the 30-day
mortality of TAVI in Japan is under 2% since 2013, achieving
noninferiority with experienced European registries and even with
the results of surgical aortic valve replacement [9]. The good
proctoring system in Japan surely contributed to the initial TAVI
results. The effort of keeping this level is strongly needed even after
ﬁnishing of proctorship. It leads to the next stage in the near future,
arrival of new valves and expansion of the indication.
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